Publications by authors named "Douglas J Jolly"

23Publications

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.

Neuro Oncol 2017 Jul;19(7):930-939

Tocagen Inc., San Diego, California; DNAtrix Inc., Houston, Texas; University of California Los Angeles, Los Angeles, California; Department of Gastroenterological Surgery, Hokkaido University, Sapporo, Japan; Department of Cell Biology and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570153PMC
July 2017

Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.

Neuro Oncol 2017 Jul;19(7):918-929

Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, California; Department of Cell Biology and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California; Tocagen Inc., San Diego, California; Department of Neurosurgery, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574670PMC
July 2017

Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studies.

Hum Gene Ther Clin Dev 2013 Mar 3;24(1):1-4. Epub 2013 Apr 3.

Department of Preclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/humc.2013.008
Publisher Site
http://dx.doi.org/10.1089/humc.2013.008DOI Listing
March 2013

Retroviral replicating vectors in cancer.

Methods Enzymol 2012 ;507:199-228

Department of Medicine, University of California, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-386509-0.00011-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197216PMC
June 2012

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

Blood 2003 Sep 22;102(6):2038-45. Epub 2003 May 22.

Division of Hematology and Oncology, Suite 3016, UC-Davis Cancer Center, University of California at Davis, 4501 X St, Sacramento, CA 95817.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-01-0167DOI Listing
September 2003

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

Blood 2003 Sep 22;102(6):2038-45. Epub 2003 May 22.

Division of Hematology and Oncology, Suite 3016, UC-Davis Cancer Center, University of California at Davis, 4501 X St, Sacramento, CA 95817.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-01-0167DOI Listing
September 2003